Format

Send to

Choose Destination
Trials. 2017 Sep 26;18(1):440. doi: 10.1186/s13063-017-2176-0.

Conducting non-commercial international clinical trials: the ICR-CTSU experience.

Author information

1
The Institute of Cancer Research Clinical Trials and Statistics Unit, ICR Clinical Trials and Statistics Unit (ICR-CTSU), 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK.
2
The Institute of Cancer Research Clinical Trials and Statistics Unit, ICR Clinical Trials and Statistics Unit (ICR-CTSU), 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK. claire.snowdon@icr.ac.uk.

Abstract

BACKGROUND:

Academic clinical trials play a fundamental role in the development of new treatments, the repurposing of existing treatments and in addressing areas of unmet clinical need. With cancer treatments increasingly targeted at molecular subtypes, and with priority placed on developing new treatments for rare tumour types, the need for international trial participation to access sufficient patient numbers for successful trial conduct is growing. However, lack of harmonisation of international legal, ethical and financial systems can make this challenging and the cost and effort of conducting trials internationally can be considered prohibitive, particularly where the sample size is comparatively small.

METHODS:

The Institute of Cancer Research - Clinical Trials and Statistics Unit (ICR-CTSU) is a UK-based academic clinical trials unit that specialises in the design, conduct and analysis of clinical trials of cancer treatments with an expanding portfolio of trials in molecular subtypes of breast and urological cancers and in other rare cancer types. Implementing appropriate mechanisms to enable international participation has therefore been imperative. In this article, we explain how we have approached the challenges involved and describe examples of successful international trial conduct, achieved through robust collaborations with academic and industry partners.

CONCLUSION:

Conducting academic trials internationally is challenging but can and should be achieved through appropriate governance mechanisms and strong collaborations.

KEYWORDS:

Academic trials; Clinical trial; International conduct; Molecular subtypes; Rare cancers

PMID:
28950887
PMCID:
PMC5615436
DOI:
10.1186/s13063-017-2176-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center